中國寶安(000009.SZ):子公司馬應龍擬轉讓所持大佛藥業全部股份
格隆匯12月13日丨中國寶安(000009.SZ)公佈,近日,公司下屬子公司馬應龍藥業集團股份有限公司(證券簡稱"馬應龍",證券代碼:600993)、華一發展有限公司、中國寶安集團控股有限公司、國發建富實業有限公司共同與杭州雲柏醫藥科技有限公司(以下簡稱"雲柏醫藥")簽署了《股權轉讓協議》,將合計持有的深圳大佛藥業股份有限公司(以下簡稱"大佛藥業")59,469,000股股份(佔大佛藥業當前總股本的86.816%)轉讓給雲柏醫藥,交易單價為4.38元/股。本次交易完成後,公司下屬子公司將不再持有大佛藥業股份,大佛藥業不再納入公司合併報表範圍。
若本次交易達成,預計增加公司淨利潤10,000萬元左右,對本年度的影響金額視交易進展而定,具體會計處理以會計師事務所審計確認的結果為準。但協議最終能否按約定履行完畢尚存在不確定性,敬請投資者注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.